HEALTH● LOWJul 29 · Jul 29, 2026, 5:47 PM
Allogene rises as FDA offers Fast Track, RMAT tags to cell therapy
Seeking Alpha Tech
Allogene's stock rose after the FDA granted Fast Track and RMAT designations to its cell therapy. This indicates expedited regulatory review for a potentially significant medical treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH8m agoEbola: Day pandemic killed an Aláàfin, By Festus AdedayoPremium TimesHEALTH35m agoAgenus reports response rate in colon cancer trialSeeking Alpha TechHEALTH57m agoEbola: NCDC expands health declaration requirement for international travellersPremium TimesHEALTHBREAKING1h agoU.S. measles cases more than double what they were last year as outbreak spreadsNPR News